Verified employee & interview reviews

Torrent Pharma Reviews

Ahmedabad, Gujarat

4.5/ 5

2 reviews

Torrent Pharmaceuticals Limited, the flagship company of the Torrent Group, is a leading Indian multinational pharmaceutical firm headquartered in Ahmedabad, Gujarat. Established in 1959 by U. N. Mehta as Trinity Laboratories, the company was rebranded as Torrent Pharmaceuticals in 1971. Today, it stands as a dominant force in the global healthcare industry, recognized for its expertise in niche marketing and its leadership across several key therapeutic segments. The company focuses heavily on chronic and sub-chronic therapies, which account for a significant portion of its revenue. It is a market leader in therapeutic areas such as cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), and women’s healthcare (WHC). Additionally, Torrent Pharma maintains a strong presence in diabetology, pain management, oncology, dermatology, and anti-infectives. Its product portfolio includes branded generics, generic formulations, over-the-counter (OTC) drugs, and active pharmaceutical ingredients (APIs). Torrent Pharma’s operational excellence is supported by eight state-of-the-art manufacturing facilities, five of which are approved by the USFDA. These facilities enable the company to serve more than 50 countries worldwide. It holds a particularly prominent position in international markets, ranking as the top Indian pharmaceutical company by market share in both Brazil and Germany. Its global strategy is further strengthened by dedicated research and development centers employing over 750 scientists focused on developing differentiated generics and biosimilars. Strategic acquisitions have been pivotal to the company's growth. Notable deals include the acquisition of Heumann Pharma in 2005 to enter the German market, the purchase of Elder Pharmaceuticals' Indian formulations business in 2013, and the acquisition of Unichem Laboratories' domestic business in 2017. More recently, in 2022, it acquired Curatio Healthcare to bolster its dermatology portfolio, and in 2025, it announced a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited. Financially, Torrent Pharmaceuticals is a robust entity listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). For the fiscal year ending March 31, 2026, the company reported an annual turnover of approximately INR 13,980 crore. As of mid-2026, its market capitalization stood at approximately $16.1 billion. The leadership team is currently led by Chairman Samir Mehta and Managing Director Aman Mehta. The company is also committed to sustainability, integrating Environmental, Social, and Governance (ESG) frameworks into its operations. This includes investing in hybrid solar-wind projects to reduce its carbon footprint and meet captive power requirements. With a workforce of over 17,000 employees, Torrent Pharma continues to advance healthcare solutions through professional integrity and advanced R&D.